HiDO HomeCareSystem: Participants randomized to the intervention arm will receive and be trained on the HiDO HCS Device and will have medication dispensed via this technology.
Study summary
The purpose of this research is to learn whether the HiDO-ALZ device can improve medication compliance and health outcomes in participants with dementia that need to take daily medication.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants must have a diagnosis of dementia.
* They must be prescribed one medication indicated for dementia symptoms such as Aricept, Namenda, or Donepezil, and be prescribed at least one additional medication.
* Participants must have an active study partner that is willing to be enrolled into the study and willing to receive messages and alerts from the HiDO-ALZ system if medications are missed. The study partner must also agree to complete surveys about the participant's ongoing health.
* Participants must be willing to allow research staff to enter their homes to install the HiDO-ALZ device and to complete study activities.
The participant's medications will be reviewed by the UCD pharmacist prior to randomization. If a participant has contraindicated medication(s), this medication will need to be removed or justified by the prescribing clinician prior to randomization. The research team and HiDO staff will work with the UCD pharmacist and prescribing clinician to resolve contraindicated medications prior to randomization. If a resolution is not possible, the participant will not be enrolled.
•MoCA score of 15 to 22 or previous MMSE score of 21 to 26 within the last 6 months.
If no test is available, the participants will be given a MoCA test after signing consent to confirm eligibility.
Exclusion Criteria
* The inability to demonstrate capacity to consent or assent as determined by the Capacity Assessment Checklist.
* Individuals who do not have a study partner/caregiver (e.g., spouse, adult child) to complete questionnaires.
* Participants with MoCA scores below 15 will be excluded as they may not be able to use the device independently.
* Participants who are unable or unwilling to complete the cognitive testing or unwilling to complete the blood tests.
Primary outcome measure(s)
Change From Baseline to 12 months in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score — baseline and 12-months The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a standardized assessment used to evaluate the severity of cognitive dysfunction. The total score is derived from multiple cognitive domains, including memory, language, praxis, and orientation. Change from baseline to the specified assessment timepoint will be analyzed, with higher scores indicating greater cognitive impairment.
Change From Baseline to 12 months for Everyday Cognition (ECog) Total Score — Baesline, 4, 8, and 12 month timepoints Everyday Cognition (ECog) is a validated questionnaire used to assess cognitively relevant functional abilities in older adults across multiple domains. The ECog total score will be calculated based on participant responses, with higher scores indicating greater perceived cognitive decline. Change from baseline to the specified assessment timepoint will be analyzed.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.